Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Boye Hansen

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
American Journal of Hematology|May 8, 2002
Aggressive growth of epithelial carcinomas following treatment with nucleoside analoguesChristian Rifbjerg Larsen, Per Boye Hansen, Nielsaage Tøffner Clausen
Ugeskrift for Laeger|October 27, 2011
[Burkitt lymphoma is a highly malign tumour with a doubling time of twenty-four hours]Ulf Christian Frølund, Signe Ledou Nielsen, Per Boye Hansen
Ugeskrift for Laeger|June 11, 2003
[Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy]Thomas Høi-Hansen, Anne M Falensteen Lauritzen, Per Boye Hansen
Ugeskrift for Laeger|October 1, 2011
[Complete remission of diffuse large B-cell lymphoma of the stomach after eradication of Helicobacter pylori]Rasmus Tetens Høeg, Anne-Marie Skau, Peter Nørgaard, et al.
Leukemia & Lymphoma|February 10, 2009
Metallothionein as a useful marker in Hodgkin lymphoma subclassificationMilena Penkowa, Brit Ladegaard Sørensen, Signe Lidou Nielsen, et al.
American Journal of Hematology|November 25, 2003
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosisHans Carl Hasselbalch, Ole Weiss Bjerrum, Bjarne Anker Jensen, et al.
Hematological Oncology|July 24, 2014
Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma RegistryMartin Bjerregaard Pedersen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, et al.
American Journal of Hematology|March 30, 2005
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraPeter Braendstrup, Ole W Bjerrum, Ove J Nielsen, et al.
Oncoimmunology|January 29, 2024
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphomaUffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, et al.
Blood|March 22, 2014
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphomaArne Kolstad, Anna Laurell, Mats Jerkeman, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
American Journal of Hematology|May 8, 2002
Aggressive growth of epithelial carcinomas following treatment with nucleoside analoguesChristian Rifbjerg Larsen, Per Boye Hansen, Nielsaage Tøffner Clausen
Ugeskrift for Laeger|October 27, 2011
[Burkitt lymphoma is a highly malign tumour with a doubling time of twenty-four hours]Ulf Christian Frølund, Signe Ledou Nielsen, Per Boye Hansen
Ugeskrift for Laeger|June 11, 2003
[Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy]Thomas Høi-Hansen, Anne M Falensteen Lauritzen, Per Boye Hansen
Ugeskrift for Laeger|October 1, 2011
[Complete remission of diffuse large B-cell lymphoma of the stomach after eradication of Helicobacter pylori]Rasmus Tetens Høeg, Anne-Marie Skau, Peter Nørgaard, et al.
Leukemia & Lymphoma|February 10, 2009
Metallothionein as a useful marker in Hodgkin lymphoma subclassificationMilena Penkowa, Brit Ladegaard Sørensen, Signe Lidou Nielsen, et al.
American Journal of Hematology|November 25, 2003
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosisHans Carl Hasselbalch, Ole Weiss Bjerrum, Bjarne Anker Jensen, et al.
Hematological Oncology|July 24, 2014
Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma RegistryMartin Bjerregaard Pedersen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, et al.
American Journal of Hematology|March 30, 2005
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraPeter Braendstrup, Ole W Bjerrum, Ove J Nielsen, et al.
Oncoimmunology|January 29, 2024
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphomaUffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, et al.
Blood|March 22, 2014
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphomaArne Kolstad, Anna Laurell, Mats Jerkeman, et al.
Pageof 3